Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012

Abstract

As part of the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program in 2012 the in vitro activity of ceftaroline and relevant comparator antimicrobials was evaluated in six Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico and Venezuela) against pathogens isolated from patients with hospital associated skin and soft tissue infections (SSTIs). The study documented that ceftaroline was highly active (MIC90 0.25mg/L/% susceptible 100%) against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus (MIC90 2mg/L/% susceptible 83.3%) and β-hemolytic streptococci (MIC90 0.008-0.015mg/L/% susceptible 100%). The activity of ceftaroline against selected species of Enterobacteriaceae was dependent upon the presence or absence of extended-spectrum β-lactamases (ESBLs). Against ESBL screen-negative Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca the MIC90 and percent susceptible for ceftaroline were (0.5mg/L/94.1%), (0.5mg/L/99.0%) and (0.5mg/L/91.5%), respectively. Ceftaroline demonstrated potent activity against a recent collection of pathogens associated with SSTI in six Latin American countries in 2012.

Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial

“…As reported by other studies in Latin America [1, 3, 18, 21], all S. aureus isolates (including MRSA) collected as part of T.E.S.T between 2004 and 2015 were susceptible to linezolid and vancomycin. Small numbers of tigecycline non-susceptible isolates were collected in the early years of the T.E.S.T.…”

Bacteremia causada por Staphylococcus aureus: Uma análise de quinze anos da sensibilidade a antimicrobianos em um hospital terciário do Brasil

“…Ao contrário, na América do Norte, verificou-se redução de 47,0% para 37,6%. 17 Em uma avaliação realizada anteriormente pelo nosso grupo com isolados de S. aureus oriundos de diversos materiais clínicos, verificou-se prevalência média de resistência para eritromicina, clindamicina e ciprofloxacina de 49,4%, 41,8% e 36,5%, respectivamente, não tendo sido verificada tendência de aumento, em um período de dez anos. 18 Ao contrário, no estudo atual, no qual foram avaliados apenas isolados de hemoculturas, os percentuais de resistência foram maiores para estes antimicrobianos e a tendência de aumento foi significativa.…”

Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections

“…This reaffirms that MRSA is a common cause of cSSTI globally, and that recent rates seem to be consistent, year-on-year. In surveillance studies of isolates from skin infections, high rates of MRSA have also been reported: Africa and the Middle East, 53.6% (883/1646) in 2012e2014 [16]; Asia-Pacific and South Africa, 31.8% in 2011 [17]; Europe, Russia and Turkey, 56.8% (1467/2583) in 2012 [18]; and Latin America, 56.0% (390/696) in 2012 [19]. The lower rates of MRSA reported by Flamm et al [17] may indicate that MRSA rates have increased in certain regions since 2011; however, rates of MRSA are also influenced by their contributing study centers and countries, which are likely to differ between studies.…”